Use of Placental MSCs and their exosomes as theragnostic agents for cancer treatment and diagnostic
Crespo-Barreda, A. ; Quintanilla, M. ; Iglesias, M. ; Mirelu, L. ; de la Vieja, A. ; Martin-Duque, P.
Resumen: P117
INTRODUCTION: The Na/ I symporter gene (hNIS) is expressed in the thyroid and allows the accumulation of iodine from the diet, to form T3 and T4 hormones. Moreover, it is widely used (i) as a reporter gene for molecular imaging (when the positron emitter isotope is I124 for PET or Tc99 for SPECT) or (ii) as a therapeutic gene for cancer therapy, mediated by the accumulation of I131. An unresolved challenge is how to direct this gene specifically to the tumoral area. Previously, our group demonstrated the migratory capacity of placental mesenchymal stem cells (MSCs), carrying an adenovirus-hNIS to tumors, with good results as theragnostic tool. However, as hNIS is expressed at the placental tissue (because transfers iodine to the foetus from the maternal blood), here we decided to study whether placental MSCs and their exosomes (1) express hNIS endogenously and therefore transfers the imaging and therapeutic potentials when administered with radioactive iodine (2) are capable to reach tumoral areas when they are intravenously injected due to the tumoral tissues extravasation.
RESULTS/ SUMMARY We proved that human placenta MSCs and their exosomes have endogenous expression of NIS, migrate specifically to the tumour and their endogenous expression of NIS is enough to image both cells or exosomes in vivo, and their accumulation caused significant therapeutic effect combined with 131I. This highlight the use of endogenous NIS expression as therapy but also to trace new metastatic nodules.
Idioma: Inglés
Año: 2019
Publicado en: HUMAN GENE THERAPY 30, 11 (2019), A53
ISSN: 1043-0342
Originalmente disponible en: Texto completo de la revista
Factor impacto JCR: 4.273 (2019)
Categ. JCR: BIOTECHNOLOGY & APPLIED MICROBIOLOGY rank: 30 / 156 = 0.192 (2019) - Q1 - T1
Categ. JCR: GENETICS & HEREDITY rank: 38 / 177 = 0.215 (2019) - Q1 - T1
Categ. JCR: MEDICINE, RESEARCH & EXPERIMENTAL rank: 40 / 138 = 0.29 (2019) - Q2 - T1
Factor impacto SCIMAGO: 1.648 - Genetics (Q1) - Molecular Medicine (Q1) - Molecular Biology (Q2)
Tipo y forma: Comunicación congreso (Versión definitiva)
Debe reconocer adecuadamente la autoría, proporcionar un enlace a la licencia e indicar si se han realizado cambios. Puede hacerlo de cualquier manera razonable, pero no de una manera que sugiera que tiene el apoyo del licenciador o lo recibe por el uso que hace. No puede utilizar el material para una finalidad comercial. Si remezcla, transforma o crea a partir del material, no puede difundir el material modificado.
Exportado de SIDERAL (2021-01-26-09:28:44)
Visitas y descargas
INTRODUCTION: The Na/ I symporter gene (hNIS) is expressed in the thyroid and allows the accumulation of iodine from the diet, to form T3 and T4 hormones. Moreover, it is widely used (i) as a reporter gene for molecular imaging (when the positron emitter isotope is I124 for PET or Tc99 for SPECT) or (ii) as a therapeutic gene for cancer therapy, mediated by the accumulation of I131. An unresolved challenge is how to direct this gene specifically to the tumoral area. Previously, our group demonstrated the migratory capacity of placental mesenchymal stem cells (MSCs), carrying an adenovirus-hNIS to tumors, with good results as theragnostic tool. However, as hNIS is expressed at the placental tissue (because transfers iodine to the foetus from the maternal blood), here we decided to study whether placental MSCs and their exosomes (1) express hNIS endogenously and therefore transfers the imaging and therapeutic potentials when administered with radioactive iodine (2) are capable to reach tumoral areas when they are intravenously injected due to the tumoral tissues extravasation.
RESULTS/ SUMMARY We proved that human placenta MSCs and their exosomes have endogenous expression of NIS, migrate specifically to the tumour and their endogenous expression of NIS is enough to image both cells or exosomes in vivo, and their accumulation caused significant therapeutic effect combined with 131I. This highlight the use of endogenous NIS expression as therapy but also to trace new metastatic nodules.
Idioma: Inglés
Año: 2019
Publicado en: HUMAN GENE THERAPY 30, 11 (2019), A53
ISSN: 1043-0342
Originalmente disponible en: Texto completo de la revista
Factor impacto JCR: 4.273 (2019)
Categ. JCR: BIOTECHNOLOGY & APPLIED MICROBIOLOGY rank: 30 / 156 = 0.192 (2019) - Q1 - T1
Categ. JCR: GENETICS & HEREDITY rank: 38 / 177 = 0.215 (2019) - Q1 - T1
Categ. JCR: MEDICINE, RESEARCH & EXPERIMENTAL rank: 40 / 138 = 0.29 (2019) - Q2 - T1
Factor impacto SCIMAGO: 1.648 - Genetics (Q1) - Molecular Medicine (Q1) - Molecular Biology (Q2)
Tipo y forma: Comunicación congreso (Versión definitiva)
Debe reconocer adecuadamente la autoría, proporcionar un enlace a la licencia e indicar si se han realizado cambios. Puede hacerlo de cualquier manera razonable, pero no de una manera que sugiera que tiene el apoyo del licenciador o lo recibe por el uso que hace. No puede utilizar el material para una finalidad comercial. Si remezcla, transforma o crea a partir del material, no puede difundir el material modificado.Exportado de SIDERAL (2021-01-26-09:28:44)
Enlace permanente:
Visitas y descargas
Este artículo se encuentra en las siguientes colecciones:
Artículos
Registro creado el 2021-01-26, última modificación el 2021-01-26